Chang M W, Ohno T, Gordon D, Lu M M, Nabel G J, Nabel E G, Leiden J M
Department of Medicine, University of Chicago, IL 60637, USA.
Mol Med. 1995 Jan;1(2):172-81.
Vascular smooth muscle cell (VSMC) proliferation following arterial injury plays a critical role in a variety of vascular proliferative disorders, including atherosclerosis and restenosis after balloon angioplasty. In this study, we tested the hypothesis that localized arterial infection at the time of balloon angioplasty with an adenovirus (ADV-tk) encoding the herpes simplex virus thymidine kinase gene (HSV-tk), followed by systemic ganciclovir administration, can inhibit VSMC proliferation and neointima formation in a well-characterized model of arterial injury and restenosis.
The left carotid arteries of 31 male Sprague-Dawley rats were subjected to balloon angioplasty and immediately infected with 2 x 10(9) pfu of either ADV-tk or a control adenovirus that does not encode a recombinant protein (ADV-delta E1). Twenty-four hours after injury, animals from each experimental group were randomized to receive a course of systemic ganciclovir (ADV-tk/+GC, ADV delta E1/+GC) or saline (ADV-tk/-GC, ADV-delta E1/-GC). VSMC DNA synthesis was measured by 5'-bromodeoxuridine (BrdU) incorporation 2-4 days after balloon injury. The extent of restenosis, expressed as the neointima to media (I/M) area ratio was determined by digital planimetry 20 days after balloon injury in each of the four treatment groups. Immunohistochemistry using a mAb to von Willebrand factor (vWF) was used to determine the effects of ADV-tk infection and ganciclovir treatment on re-endothelialization of the carotid arteries 20 days following balloon angioplasty.
Forty-one percent of the medial VSMCs in the ADV-tk/-GC arteries were labeled with BrdU 4 days after balloon injury. In contrast, ADV-tk infected animals that were treated with systemic ganciclovir (ADV-tk/+GC) displayed a 40% reduction in BrdU-staining medial VSMCs (p < 0.03). I/M area ratios of the three control groups were 1.17 +/- 0.18 (ADV-tk/-GC, n = 5), 1.15 +/- 0.10 (ADV-delta E1/+GC, n = 6), and 0.91 +/- 0.08 (ADV-delta E1/-GC, n = 6). These differences were not statistically significant (p > 0.05). In contrast, the ADV-tk/+GC animals (n = 6) displayed an I/M area ratio of 0.49 +/- 0.13 which was significantly lower than that seen in each of the three control groups (p < 0.02). None of the treated animals showed evidence of significant organ toxicity at autopsy. A regenerated endothelium was observed in the ADV-tk/+GC animals 20 days after balloon injury.
Localized arterial infection with ADV-tk at the time of balloon angioplasty followed by systemic ganciclovir therapy reduces VSMC proliferation and neointimal expansion in the rat carotid artery injury model. Moreover, combined treatment with ADV-tk and systemic ganciclovir does not result in systemic toxicity and appears to selectively eliminate proliferating VSMCs, while preserving the capacity of the injured arterial segments to re-endothelialize within 3 weeks of injury. Taken together, these results support the feasibility of using this gene therapy approach for the treatment of human vascular proliferative disorders.
动脉损伤后血管平滑肌细胞(VSMC)增殖在多种血管增殖性疾病中起关键作用,包括动脉粥样硬化和球囊血管成形术后再狭窄。在本研究中,我们验证了以下假说:在球囊血管成形术时用编码单纯疱疹病毒胸苷激酶基因(HSV-tk)的腺病毒(ADV-tk)进行局部动脉感染,随后全身给予更昔洛韦,可在一个特征明确的动脉损伤和再狭窄模型中抑制VSMC增殖和新生内膜形成。
对31只雄性Sprague-Dawley大鼠的左颈动脉进行球囊血管成形术,并立即用2×10⁹ pfu的ADV-tk或不编码重组蛋白的对照腺病毒(ADV-ΔE1)进行感染。损伤后24小时,将每个实验组的动物随机分为接受全身更昔洛韦疗程(ADV-tk/+GC,ADV ΔE1/+GC)或生理盐水(ADV-tk/-GC,ADV-ΔE1/-GC)。在球囊损伤后2 - 4天,通过5'-溴脱氧尿苷(BrdU)掺入法测量VSMC DNA合成。在球囊损伤后20天,通过数字图像分析测定四个治疗组中每个组的再狭窄程度,以新生内膜与中膜(I/M)面积比表示。使用抗血管性血友病因子(vWF)单克隆抗体的免疫组织化学方法,来确定ADV-tk感染和更昔洛韦治疗对球囊血管成形术后20天颈动脉再内皮化的影响。
球囊损伤后4天,ADV-tk/-GC动脉中41%的中膜VSMC被BrdU标记。相比之下,但接受全身更昔洛韦治疗的ADV-tk感染动物(ADV-tk/+GC)中,BrdU标记的中膜VSMC减少了40%(p < 0.03)。三个对照组的I/M面积比分别为1.17±0.18(ADV-tk/-GC,n = 5)、1.15±0.10(ADV-ΔE1/+GC,n = 6)和0.91±0.08(ADV-ΔE1/-GC,n = 6)。这些差异无统计学意义(p > 0.05)。相比之下,但ADV-tk/+GC组动物(n = 6)的I/M面积比为0.49±0.13显著低于三个对照组中的每一组(p < 0.02))。在尸检时没有一只治疗动物显示出明显的器官毒性迹象证据在尸检时,没有一只接受治疗动物显示出明显器官毒性的证据。在球囊损伤后20天,在ADV-tk/+GC组动物中观察到再生的内皮。
在球囊血管成形术时用ADV-tk进行局部动脉感染,随后进行全身更昔洛韦治疗,可减少大鼠颈动脉损伤模型中的VSMC增殖和新生内膜扩张。此外,ADV-tk与全身更昔洛韦联合治疗不会导致全身毒性,似乎能选择性地消除增殖的VSMC,同时保留损伤动脉段在损伤后3周内重新内皮化的能力。综上所述,这些结果支持了使用这种基因治疗方法治疗人类血管增殖性疾病的可行性。